Drugs / GSK2231395A
last change Jun 2010 re-read 2 minutes ago

GSK2231395A

Vaccine

Developed for
haemophilus infectious disease · pneumococcal infection
Investigated by
GlaxoSmithKline

Trials 2 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00849069 Mar → Apr 2009 haemophilus infectious disease, pneumococcal infection GlaxoSmithKline Terminated No outcome recorded
Phase 1 NCT00814489 Jan → May 2009 haemophilus infectious disease, pneumococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GSK2231395A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849069
1

NCT00814489

Modality Vaccine “GSK2231395A candidate vaccineNCT00849069